First AD

Second AD

DeFi: Nirogacestat in Patients with Progressing Desmoid Tumors

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Advancements in the Treatment of Desmoid Tumors

Peer Exchange

Jonathan Trent, MD, PhD, discusses the rationale and design of the DeFi study, instrumental in the FDA approval of nirogacestat, and explores key efficacy and safety findings from this research.

An Overview of the Landscape Surrounding Desmoid Tumors

Expert Perspectives on the Pathogenesis and Diagnosis of Desmoid Tumors

Signs and Symptoms of Desmoid Tumors and Their Impact on Quality of Life

Active Surveillance in Frontline Management of Desmoid Tumors

The Evolving Role of Surgery in the Management of Desmoid Tumors

Treatment Strategies Using Radiotherapy or Other Locoregional Approaches in Desmoid Tumors

Approaches to Systemic Therapy in Desmoid Tumors: The Role of Chemotherapy

The Role of Supportive Care Measures in Patients with Desmoid Tumors

Desmoid Tumors in Women: Special Considerations for Pregnancy and Contraception

Targeting NOTCH Pathway Signaling with Nirogacestat

Impact of Nirogacestat on Pain, Quality of Life, and Fertility in Patients with Desmoid Tumors

Nirogacestat's Impact on the Future Treatment of Desmoid Tumors

Future Perspectives on the Treatment of Desmoid Tumors